These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9918413

  • 1. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M, Stevens G.
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [Abstract] [Full Text] [Related]

  • 2. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

  • 3. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E, Stern S, Guichard M.
    Cancer Radiother; 2000 Jul; 4(3):217-22. PubMed ID: 10897765
    [Abstract] [Full Text] [Related]

  • 4. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 5. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
    Lambin P, Guichard M, Chavaudra N, Malaise EP.
    Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
    [Abstract] [Full Text] [Related]

  • 6. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Jul; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 7. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
    Lartigau E, Guichard M.
    Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
    [Abstract] [Full Text] [Related]

  • 8. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM, Lemmon MJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
    [Abstract] [Full Text] [Related]

  • 9. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ, Moini M, Giuliano J, Westra WH.
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

  • 11. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 12. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
    Zeman EM, Brown JM.
    Int J Radiat Biol; 1991 Jan 15; 59(1):117-31. PubMed ID: 1671059
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 15. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM, Lemmon MJ.
    Int J Radiat Oncol Biol Phys; 1991 Mar 15; 20(3):457-61. PubMed ID: 1995531
    [Abstract] [Full Text] [Related]

  • 16. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
    Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ, Carmichael J.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):369-72. PubMed ID: 8195035
    [Abstract] [Full Text] [Related]

  • 17. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL.
    Acta Oncol; 1995 May 15; 34(3):301-5. PubMed ID: 7779413
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ.
    Br J Cancer; 1997 May 15; 76(10):1338-47. PubMed ID: 9374381
    [Abstract] [Full Text] [Related]

  • 19. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 20. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
    Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, Cho KH.
    J Cancer Res Clin Oncol; 2008 Mar 15; 134(3):397-404. PubMed ID: 17724612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.